38 results about "Phenylalanine dehydrogenase" patented technology

The instant invention is drawn to the methods and compositions necessary to provide recombinant proteins with a substantially reduced or eliminated content of norleucine or other non-standard amino acids. Various embodiments of the invention provide for the substantial elimination of the incorporation of non-standard amino acids into recombinant proteins by the co-expression or enhanced expression of a protein (or the enzymatically active portion thereof) capable of degrading norleucine or other non-standard amino acids, including norvaline, beta-methylnorleucine, and homoisoleucine. In certain particular embodiments of the invention, the norleucine is degraded by a glutamate dehydrogenase, a leucine dehydrogenase, a valine dehydrogenase, a phenylalanine dehydrogenase, a glutamate/leucine/phenylalanine/valine dehydrogenase, or an opine dehydrogenase. Also provided are the cells and DNA constructs for carrying out these methods.

A process for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV is provided which employs a BOC-protected amine of the structure

prepared by subjecting an acid of the structure

to reduce amination by treating the acid with ammonium formate, nicotinamide adenine dinucleotide, dithiothreitol and partially purified phenylalanine dehydrogenase/formate dehydrogenase enzyme concentrate (PDH/FDH) and without isolating treating the resulting amine of the structure 2

with di-tert-butyl dicarbonate to form the BOC-protected amine.

The invention provides a phenylalanine dehydrogenase (PDH) mutant derived from geobacillus, which is high in enzyme activity and thermal stability compared to wild PDH. Furthermore, the invention provides a method for catalytic synthesis of a saxagliptin chiral intermediate, namely (S)-N-t-butyloxycarbonyl-3-hydroxy-1-adamantyl-D-glycine (Boc-HAG) through the PDH mutant. According to the method provided by the invention, Boc-HAG can be directly prepared through a reaction in two steps, and e.e. (enantiomeric excess) value exceeds 99.9%; generation of side products can be reduced, yield of 95% can be achieved within 12 hours, catalysis time is greatly shortened, energy consumption is reduced and a post-treatment process is simplified.

The invention discloses a process method for preparing single optical pure L-homophenylalanine by using L-homophenylalanine dehydrogenase as a biological catalyst. The method particularly comprises the following steps of: adding a substrate, ammonium formate, the L-homophenylalanine dehydrogenase and a formate dehydrogenase mediated coenzyme recycling and regenerating system into reaction liquid; after reacting under an oscillating or stirring condition, filtering from the reaction system to directly obtain an L-homophenylalanine product; and circulating the filtrate for the next reaction, wherein the reaction temperature is between 15 and 40 DEG C. The L-homophenylalanine is prepared by coordinating the L-homophenylalanine dehydrogenase with the coenzyme recycling and regenerating system and by adopting a simple filtering circulation process, wherein the substrate concentration reaches 560 mM; the NAD+ concentration of the required coenzyme is low; the coenzyme can be recycled and reused for many times, so that the cost of the coenzyme can be ignored; the yield excesses 95 percent; and important application value is achieved.

The present invention provides compositions and methods of treating hyperphenylalaninemia (e.g., phenylketonuria) in a subject in need thereof comprising administering to the subject an effective amount of a phenylalanine dehydrogenase (PheDH) polypeptide. The present invention also provides pharmaceutical formulations comprising PheDH for lowering the phenylalanine concentration in the subject (e.g., in the intestines and/or blood).

The invention discloses a method for realizing whole cell transformation to synthesize L-phenyllactic acid by a genetic engineering strain, in particular to a genetic engineering strain capable of co-expressing phenylalanine dehydrogenase and L-hydroxyisocaproic acid reductase to realize self-circulation of cofactors NAD<+> and NADH. The method for synthesizing L-phenyllactic acid by a whole celltransformation substrate L-phenylalanine belongs to the field of bioengineering technology. By using the whole cell transformation of a recombinant strain E.coli BL21(DE3)/pET28a-pdh-ldh to synthesizeL-phenyllactic acid, the whole cell transformation rate can reach 88.9% to 95.6% under the action of an added surfactant. By adopting the method, the self-circulation of the cofactors NAD<+> and NADHis realized, the addition amount of the cofactors is reduced, the production cost is reduced, and the method has a broad application prospect in the field of industrial synthesis of L-phenyllactic acid.

The invention discloses a method for immobilization of phenylalanine dehydrogenase by chemical reduced graphene oxide, and belongs to the technical field of immobilized enzyme. The chemical reduced graphene oxide is stable in structure, is good in biocompatibility, and is a good enzyme immobilization carrier. The surface of the chemical reduced graphene oxide with a sheet-layer structure is lack of groups such as an epoxy group, a carbonyl group and a carboxyl group, is great in load area, and has hydrophobicity. The immobilization of phenylalanine dehydrogenase by the chemical reduced graphene oxide mainly has a hydrophobic effect; and in an immobilization process, the degree of reduction and salt concentration of the chemical reduced graphene oxide have influences on immobilization of enzyme by the chemical reduced graphene oxide. The obtained immobilized phenylalanine dehydrogenase is obviously improved in pH stability and repeated use stability, and meanwhile, has relatively high enzyme activity recovery rate. The method disclosed by the invention has the advantages that the process is simple; the preparation conditions are mild; and the immobilization rate is high.

The invention discloses a Beta-cypermethrin degrading bacterium. The bacterial strain is bacillus licheniformis B-1; the GenBank accession number of 16S rDNA is HQ009796. The strain is from soil of atea garden, and is obtained through Beta-cypermethrin concentration gradient domestication, preliminary screening, separation and purification and secondary screening. The bacterial colony edge of thestrain is reddish color; the center is white; the surface is dry and has drapes; the edge is irregular; the single thallus is in a rod shape and is gram positive; the spore is elliptical and is mesic; the sporocyst is slightly inflated; glucose, arabinose, xylose and mannite are positive; gelatin and starch can be hydrolyzed; phenylalanine dehydrogenase and yolk lecithin enzyme are negative; theanaerobic growth can be realized. Under the proper conditions, the degrading rate of the strain on the Beta-cypermethrin with the concentration being 16.5mu g/mL in a culture medium is 94.12 percent.

The invention discloses amino acid dehydrogenase and application thereof. The amino acid dehydrogenase is obtained by mutating amino acid dehydrogenase shown as SEQ ID NO.01, mutation includes at least one of the following: L at the 57 bit is mutated into E, G at the 60 bit is mutated into S or T, K at the 76 bit is mutated into S, Y at the 285 bit is mutated into L or M, N at the288 bit is mutated into E, and M at the 333<rd> bit is mutated into D or R. By modifying molecules of phenylalanine dehydrogenase obtained from a marine strain, namely bacillus nanhaiensis, a substrate binding pocket of the phenylalanine dehydrogenase is remodeled, large steric hindrance substrates can be accommodated, meanwhile, the substrates are brought closer to coenzyme, thus the amino acid dehydrogenase obtains catalytic activity to the large steric hindrance substrates, and the catalytic function of the amino acid dehydrogenase is expanded for the biosynthetic series of non-naturalamino acids with large steric hindrance hydrophobic side chains.

The invention provides a synthetic method of L-heterocyclic amino acid and a pharmaceutical composition with L-heterocyclic amino acid. The synthetic method comprises the steps that A, heterocyclic ketonic acid is prepared, wherein heterocycle in heterocyclic ketonic acid is selected from any one of pentabasic single heterocycle, hexabasic single heterocycle, heptabasic single heterocycle, pentabasic alkylation single heterocycle, hexabasic alkylation single heterocycle and heptabasic alkylation single heterocycle, and a structural formula of ketonic acid base in heterocyclic ketonic acid is as shown in the specification, and is positioned in any carbon position of heterocycle; and B, heterocyclic ketonic acid is mixed with ammonium formate, phenylalanine dehydrogenase, formate dehydrogenase and coenzyme NAD<+> to perform a reduced amination reaction to generate L-heterocyclic amino acid, wherein an amino acid sequence of phenylalanine dehydrogenase is SEQ ID No. 1 (sequence identifier number 1). Since special phenylalanine dehydrogenase, formate dehydrogenase and coenzyme NAD<+> are used for allowing heterocyclic ketonic acid to perform the reduced amination reaction to generate L-heterocyclic amino acid, the raw material conversion rate is high and the chiral selectivity is high.

The invention discloses phenylalanine dehydrogenase as well as a preparation method and application thereof, and relates to strain culture, enzyme expression, separation and purification, detection ofionic liquid tolerance and organic solvent system tolerance of enzymes and the like. According to the invention, high-stability phenylalanine dehydrogenase which is resistant to an organic solvent and an ionic liquid and is required by industrial biological catalysis application is obtained. The phenylalanine dehydrogenase has the characteristics of good stress resistance and high stability in anon-aqueous phase system, can effectively prolong the half-life period and improve the catalytic efficiency in industrial production, achieves the purpose of reducing the production cost, and has important industrial application value.

The invention relates to an amine dehydrogenase mutant and its application in the synthesis of chiral amine and aminoalcohol. Specifically, the present invention discloses an amphetamine dehydrogenase mutant and its corresponding amino acid sequence obtained by molecular engineering of Geobacillus kaustophilus phenylalanine dehydrogenase, and the amphetamine The use of dehydrogenase mutants in the synthesis of chiral amines and chiral amino alcohols by asymmetric reductive amination of latent chiral carbonyl compounds. Compared with the synthesis methods of other chiral amines and chiral amino alcohols, the ammonia donor used in the present invention is cheap ammonia water, the formed by-product is only clean water, and the optical purity of the products is >99%, so it represents A biosynthesis method with mild reaction, high stereoselectivity, and environmental protection has been developed, which has a good application prospect in the actual production of chiral amines and chiral amino alcohols.

The invention relates to a method for detecting the content of phenylalanine and tyrosine by an enzyme method, and an application thereof. The method uses phenylalanine dehydrogenase to quickly and correctly characterize the content of phenylalanine and phenylalanine in a system by the increasing of the content of NADH. The total content of phenylalanine and tyrosine in a sample can be quickly determined by the end point method or the initial velocity method. The method has high sensitivity, rapid and stable detection, good repeatability, simple and convenient operation, relatively low cost and relatively wide application range.

The invention belongs to the technical field of bioengineering and relates to a method for preparing recombinant L-phenylalanine hydroxylase, in particular to a method for obtaining high-yield L-phenylalanine hydroxylase by embedding a programmable microorganism source L-phenylalanine hydroxylase gene into an appropriate expression vector to establish recombinant plasmid and a transformed cell and using a simple and effective affinity method. The L-phenylalanine hydroxylase obtained by the method has high yield, high activity and simple and convenient production method. The invention also comprises the new recombinant plasmid and transformed cell established in the method. The L-phenylalanine hydroxylase prepared by the method can be used for developing a screening reagent of newborn phenylketonuria and producing L-phenylalanine.